---
figid: PMC9526656__ECAM2022-3498310.006
pmcid: PMC9526656
image_filename: ECAM2022-3498310.006.jpg
figure_link: /pmc/articles/PMC9526656/figure/fig6/
number: Figure 6
figure_title: ''
caption: 'The effect of Jatrorrhizine on inflammatory cytokines levels in mice with
  UC.; (a) The levels of IL-1β in serum; (b) The levels of TNF-α in colon tissue;
  (c) The levels of MPO in colon tissue. (d) The levels of IL-10 in colon tissue;
  (e) The levels of TGF-β in colon tissue. All data were presented as mean ± SD. (Ctrl:
  control group; DSS: model group; 5-ASA: mesalazine group; Jat L: Jatrorrhizine 40 mg/kg
  dose group; Jat M: Jatrorrhizine 80 mg/kg dose group; Jat H: Jatrorrhizine 160 mg/kg
  dose group; ∗p < 0.05 and ∗∗p < 0.01 vs. Control group; #p < 0.05 and ##p < 0.01
  vs. DSS group).'
article_title: Jatrorrhizine Alleviates DSS-Induced Ulcerative Colitis by Regulating
  the Intestinal Barrier Function and Inhibiting TLR4/MyD88/NF-κB Signaling Pathway.
citation: Shengqi Niu, et al. Evid Based Complement Alternat Med. 2022;2022:3498310.
year: '2022'

doi: 10.1155/2022/3498310
journal_title: 'Evidence-based Complementary and Alternative Medicine : eCAM'
journal_nlm_ta: Evid Based Complement Alternat Med
publisher_name: Hindawi

keywords:
---
